Clinical Trial Update: This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated BI 409306 for attenuated psychosis syndrome (a type of psychotic disorder) to assess tolerability and potential efficacy over one year…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attenuated Psychosis Syndrome
• Psychotic Disorders

Drugs mentioned

• BI 409306

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psychotic Disorders | Phase 2 | Status: TERMINATED | Results posted: 2022-06-29